TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Clinical Performance and Safety of LiquiBand FIX8® Versus AbsorbaTack™ for Hernia Mesh Fixation and Peritoneal Closure in Groin Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Is male or female, ≥22 years of age~Is willing and able to give written informed consent~Has a primary or recurrent groin hernia (unilateral or bilateral, inguinal or femoral)~Is currently scheduled and eligible for TAPP or TEP laparoscopic groin hernia repair (inguinal or femoral)~Hernia mesh to be used at the time of surgery is at least 4 x 6 in size and is one of the following;~* 3D Max™ Mesh (Bard Inc.)~* 3D Max™ Light (Bard Inc.)~* Parietex™ 2D (order code starting with TEC) Flat Sheet Mesh (Medtronic)~* Parietex™ 3D (order code starting with TET) Flat Sheet Mesh (Medtronic)~Is willing and able to comply with the protocol assessments at time of surgery and during the post surgical follow up period~Exclusion Criteria:~Has a hernia type not suitable for laparoscopic hernia repair as determined by the Investigator (i.e. strangulated)~Subject has a recurrent groin hernia previously repaired laparoscopically, has an anatomical defect or had prior surgical procedures that in the opinion of the Investigator prevents access to the pre-peritoneal space for TAPP or TEP laparoscopic hernia repair~Is pregnant or actively breastfeeding~Has a known sensitivity to cyanoacrylate or formaldehyde,D\&C Violet No.2 dye or any component of LiquiBand FIX8® or control device~Has an active or potential infection at the surgical site or systemic sepsis~Hernia mesh to be used at surgery is less than 4x6 in size, or not one of the types of mesh listed in Inclusion Criteria above~Cannot tolerate general anaesthesia~Has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LiquiBand FIX8® (Type: EXPERIMENTAL): LiquiBand FIX8® is an n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
- AbsorbaTack™ (Type: ACTIVE_COMPARATOR): AbsorbaTack™ is an absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had a diagnosis of palmoplantar pustulosis for at least 24 weeks as of the time of informed consent.~* Subject has a PPPASI total score ≥12 and a PPPASI severity score of pustules/vesicles on the palms or soles ≥2 both at the pre-examination and enrollment examination;~* Subject inadequately responded to any one or combination of the following therapies before informed consent: Topical corticosteroids, Topical vitamin D3, Phototherapy, Etretinate~Exclusion Criteria:~* Subject has a diagnosis of plaque psoriasis, pustular psoriasis, drug-induced palmoplantar pustulosis, or pompholyx;~* Subject has an improvement in PPPASI total score of ≥4 points during the screening period;~* Subject has a history or evidence of psychiatric disorder or alcohol/drug abuse that, in the opinion of the investigator or subinvestigator, may compromise the safety of the subject because of participation in the study or may interfere with assessments and procedures in the study or study completion;~* Subject has a past or current history of suicidal ideation (severity of 4 or 5) or any suicidal behavior at enrollment, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS);~* Subject has severe depression with a PHQ-8 total score of ≥15 at enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- KHK4827 210mg Q2W SC (Type: EXPERIMENTAL): None
- Placebo Q2W SC (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with pancreatic, duodenal, or small intestine fistula~* Patient with simple, externalised fistula~* Patient with fistula for which a medical conservative treatment is considered~* Patient with:~* for pancreatic fistulae: a mean drainage volume more than or equal to 100 ml/24h over 48 hours or more than or equal to 50 ml / 24h over 3 days and a concentration of amylase in the drainage fluid 3 times higher than in the serum over at least 2 or 3 consecutive days respectively,~* for duodenal and small intestine fistulae: a mean drainage volume more than or equal to 100ml/24h over 2 days~Exclusion Criteria:~* Patient expected to require a surgical treatment of the fistula during the study~* Patient having uncontrolled intra-abdominal sepsis; Crohn's disease; radiotherapy lesions of the small bowel; a mesenteric vascular insufficiency; a fistula localised in cancer-infiltrated areas; a distal obstruction; an exposed fistula of the small intestine; or intra-abdominal foreign bodies.~* Patient receiving long-term corticotherapy~* Patient having received any somatostatin analogue as curative treatment of the fistula or any PRF somatostatin analogue within the previous month.~* Patient having previously undergone a transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped.
- 2 (Type: PLACEBO_COMPARATOR): One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Medical diagnosis of COPD~* Current or prior history of cigarette smoking~Exclusion Criteria:~* Medical diagnosis of asthma~* Chest X-ray diagnostic of significant disease other than COPD~* Significant condition or disease other than COPD

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hyperlipoproteinemia Type I or Type V willing and medically able to discontinue their lipid lowering medication (if prescribed).~* Non breast feeding women.~* Women of child bearing potential practicing appropriate contraception with a negative pregnancy test before dosing.~Exclusion Criteria:~Patients with:~* uncontrolled type 1 or type 2 diabetes mellitus,~* active pancreatitis (the month prior to study start),~* history of drug or alcohol abuse within the 12 months prior to dosing,~* or any surgical or medical condition, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LCQ908 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Reduction by Early Acarbose Treatment in Basal Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-79 years~* Type 2 diabetes inadequately controlled with insulin glargine alone or in combination with metformin~  * Diagnosed of type 2 diabetes for at least 6 months prior to screening~ * Treated with tolerable, stable dose of insulin glargine and/or metformin for at least 3 months prior to screening~ * HbA1C \> 7.0 and \</= 10.0% at screening~Exclusion Criteria:~* Type 1 diabetes patients~* Myocardial infarction, unstable angina or coronary artery bypass surgery within previous 6 months~* Clinical evidence of active liver disease, or serum ALT or AST 3 times the upper limit of the normal (ULN) range~* Serum creatinine \>/= 1.5 mg/dl for males, \>/= 1.4 mg/dl for females~* Active proliferative diabetic retinopathy~* Any other anti-diabetic medications except insulin glargine and metformin within 4 weeks prior to study entry~* Gastrointestinal diseases that are likely to be associated with abnormal intestinal motility or altered absorption of nutrients (e.g. gastroparesis, malabsorption syndrome, chronic diarrhea states, enteropathies, inflammatory bowel disease, partial intestinal obstruction, and large hernias)~* Galactose intolerance~* Pregnancy~* Delivery, abortion, or lactation within less than three cycles before the start of treatment~* No use of contraceptive in childbearing aged. Women of childbearing potential must agree to use adequate contraception (barrier method of birth control) since signing of the informed consent form until at least 30 days after the last study drug administration.~* Hypersensitivity to the active substances or any of gradient of the study drug ingredients~* Treatment with any medication including corticosteroid or herb medication that can affect blood glucose level in the 3 months prior to study entry~* Any disease or condition that in the opinion of the investigator may interfere with completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer~* Age 18-60 years old~* Non-smoker~* must be able to fast 8 hours prior to exposure visits and for a further 4 hours during the exposure~Exclusion Criteria:~* Subjects must not be regularly taking multivitamins, vitamins C \& E, folate, medications, fish oil or aspirin, oral or inhaled steroids, for 4 weeks before and during the trial.~* Lipid abnormalities~* Asthma or respiratory disease~* Hypertension (Bp\> 140/90) or taking any blood pressure drug~* Known cardiac disease~* abnormal homocysteine or glucose levels

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- methyl donor (Type: EXPERIMENTAL): Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
- placebo (Type: PLACEBO_COMPARATOR): placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Moxonidine for Prevention of Post-ablation AFib Recurrences

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertensive patients with paroxysmal atrial fibrillation.~* At least two documented episodes within the last 12 months (either self-terminating within 7 days or cardioverted, medically or electrically, in less than 48 hours).~* At least one episode should have been documented under treatment with a class Ic or III antiarrhythmic drug.~Exclusion Criteria:~1. age \<25 or \>80 years~2. presence of atrial thrombus~3. left atrial volume index \>55 ml/m2~4. hypersensitivity to moxonidine~5. sick sinus syndrome or sino-atrial block~6. 2nd or 3rd degree atrioventricular block~7. bradycardia (below 50 beats/minute at rest)~8. estimated glomerular filtration rate \<40 ml/min/1.73 m2~9. history of angioneurotic oedema~10. heart failure symptoms OR impaired left ventricular function (EF \<40%), even if asymptomatic~11. stable or unstable angina pectoris~12. intermittent claudication or known peripheral artery disease~13. Parkinson's disease~14. epileptic disorders~15. glaucoma~16. history of depression~17. pregnancy or lactation~18. inability or unwillingness to adhere to standard treatment or to provide consent.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal \<= 140/90).
- Moxonidine group (Type: ACTIVE_COMPARATOR): Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal \<= 140/90).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot fMRI Study of TMS in Late-Life Severe Worry

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have completed Dr. Andreescu's study R01MH108509/PRO15080120.~* Penn State Worry Questionnaire score of 55 or above.~Exclusion Criteria:~* Any form of psychosis or Bipolar Disorder, dementia, a history of substance abuse within the last six months~* Use of antidepressants within the last five to fourteen days (adequate washout interval to be determined by the principal investigator (PI) based on each specific antidepressant). For fluoxetine, the washout interval will be six weeks. However, for participants who are prescribed low dose psychotropics for pain, sleep disturbances, and/or medical conditions (e.g. amitriptyline for peripheral neuropathy, low dose trazodone as a sleep aid), these will be allowed in most circumstances. We will include participants on certain dosages of the most commonly prescribed antidepressants (for medical reasons) as follows: amitriptyline up to 50 mg/d, doxepin up to 50 mg/d, trazodone up to 100 mg/d, and imipramine up to 50 mg/d. We will review other cases individually and the PI will decide if the participants are eligible for the study and if they may continue the current medication.~* Unable to complete MRI scans: presence of ferromagnetic metal in the body, claustrophobia~* Contraindications for TMS:~  1. Presence of a neurologic disorder or medical condition known to alter seizure threshold(e.g., stroke, aneurysm, brain surgery, structural brain lesion, brain injury, frequent/severe headaches)~ 2. Recurrent seizures or epilepsy in participant~ 3. Pregnancy~ 4. Metallic implants in body located at 30 cm or less from the position of the magnetic coil; presence in the body of other devices that may be affected by magnetic field (e.g. pacemakers).~* Unable to temporarily discontinue benzodiazepines 48 hours prior to MRI scan. Participants on high doses of benzodiazepines (e.g., greater than or equivalent to 2 mg of lorazepam) will be excluded, given the complexity and potential complications of benzodiazepine taper/withdrawal.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcranial magnetic stimulation (TMS) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females ages 18 to 64~* Prior history of elevated nighttime blood pressure (BP) ((systolic blood pressure (SBP) \> 115mmHg))~* Taking no more than 2 antihypertensive medications~* African American (self-defined by the participant)~Exclusion Criteria:~* Secondary forms of hypertension~* Presence of other diseases requiring treatment with BP lowering medication~* Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or history of cerebrovascular disease, including stroke and transient ischemic attacks)~* Diabetes mellitus (Type 1 or 2)~* Cancer/malignancy other than nonmelanoma skin cancer~* Primary renal disease~* Serum creatinine \> 1.5 mg/dL in men or \> 1.4 mg/dL in women~* Severe anemia~* Liver enzymes \> 2.5 times upper limits of normal~* Hepatitis B, Hepatitis C, or HIV positive as assessed by questionnaire~* Current treatment with or regular use of calcium channel blocking agents, cyclooxygenase-2 inhibitors (COX2-I), oral contraceptives, estrogen, sildenafil, vardenafil, tadalafil, antidepressants, corticosteroids, or warfarin~* Current use of melatonin or any sleep aids containing melatonin~* Regular consumption (1 or more times per week) of: Vitamin methyl B12, St. Johns Wort, feverfew, black and white mustard seeds, wolf berry seed~* Severe Sleep apnea~* Night work~* Women who are pregnant, breast feeding, attempting conception, or planning to attempt conception over the next 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the treatment period of Study ALK9072-003EXT~* Continues to require chronic treatment with an antipsychotic medication~* Continues to reside in a stable living situation~* Continues to have an identified reliable informant~Exclusion Criteria:~* Abnormal clinical laboratory value, vital sign, or electrocardiogram (ECG) finding during participation in Study ALK9072-003EXT that was clinically relevant and related to study drug~* Missed more than 1 scheduled study visit during participation in the preceding Study ALK9072-003EXT~* Has a significant or unstable medical condition that would preclude safe completion of the current study~* Subject is pregnant or breastfeeding~* Subject expects to be incarcerated, or has pending legal action which may impact compliance with study participation or procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 9072, Low Dose (Type: EXPERIMENTAL): None
- ALKS 9072, High Dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete